Arcus Biosciences IncRCUS
Price$25.83Intrinsic value$20.8619% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $57M+11.8% YoYTTM through 30 Jun 2026
Net Income -$460MTTM through 30 Jun 2026
Free Cash Flow -$475MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-835.1%
Operating Margin-788.2%
Net Margin-807.0%

Returns

-99.1%ROE
-49.8%ROA

Balance Sheet Health

Debt / Equity0.19x
Current Ratio3.82x
Net Debt-$776Mnet cash position
Cash & Equivalents$150M

Quality Metrics

Altman Z-Score0.88
Piotroski F-Score1 / 9
FCF Margin-833.3%
Rule of 40-800.6
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'17'18'19'22'23'24'25
FY2025: $247M
Diluted EPS-$3.94TTM
'19'20'21'22'23'24'25
FY2025: $-3.29

Dividend

No dividend

Capital Allocation

Capex Intensity1.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.